Neurotrophic Keratitis
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BRIM BiotechnologyTaiwan - Taipei
1 program1
BRM424 Ophthalmic Solution - Dose1Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BRIM BiotechnologyBRM424 Ophthalmic Solution - Dose1
RecordatiUdonitrectag
Clinical Trials (2)
Total enrollment: 108 patients across 2 trials
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Start: Jul 2024Est. completion: Nov 2025
Phase 2Recruiting
REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Start: Oct 2020Est. completion: Apr 2024108 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 108 patients
2 companies competing in this space